Literature DB >> 25106866

Clinical trials in neurosurgical oncology.

Meghan Murphy1, Ian F Parney.   

Abstract

Brain tumors such as diffuse infiltrating gliomas continue to represent a major clinical challenge. Overall survival for patients diagnosed with glioblastoma, the most common primary brain tumor, remains less than 2 years despite intensive multimodal therapy with surgery, radiation, and chemotherapy. However, advances have been made in standard therapies and novel treatments that are showing great potential. These advances reflect careful study performed in the context of clinical trials. Neurosurgeons have played and will continue to play key parts in these studies. In this manuscript, we review clinical trials in neuro-oncology from a neurosurgical point of view and discuss potential roles for neurosurgeons in advancing glioma therapy in the future.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25106866     DOI: 10.1007/s11060-014-1569-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  78 in total

1.  Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.

Authors:  G Evren Keles; Edward F Chang; Kathleen R Lamborn; Tarik Tihan; Chih-Ju Chang; Susan M Chang; Mitchel S Berger
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

Review 2.  Heat shock protein-peptide complex in the treatment of glioblastoma.

Authors:  Alfred P See; Gustavo Pradilla; Isaac Yang; Seunggu Han; Andrew T Parsa; Michael Lim
Journal:  Expert Rev Vaccines       Date:  2011-06       Impact factor: 5.217

3.  Value of surgical intervention in the treatment of glioma.

Authors:  M R Quigley; N Flores; J C Maroon; B Sargent; S Lang; A Elrifai
Journal:  Stereotact Funct Neurosurg       Date:  1995       Impact factor: 1.875

4.  A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.

Authors:  J C Buckner; P J Schomberg; W L McGinnis; T L Cascino; B W Scheithauer; J R O'Fallon; R F Morton; S A Kuross; J A Mailliard; A K Hatfield; J T Cole; P D Steen; A M Bernath
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

5.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

6.  Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma.

Authors:  Shota Tanaka; Fredric B Meyer; Jan C Buckner; Joon H Uhm; Elizabeth S Yan; Ian F Parney
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

7.  Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.

Authors:  Robert M Prins; Horacio Soto; Vera Konkankit; Sylvia K Odesa; Ascia Eskin; William H Yong; Stanley F Nelson; Linda M Liau
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

8.  Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.

Authors:  B Jeremic; D Grujicic; V Antunovic; L Djuric; M Stojanovic; Y Shibamoto
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-12-01       Impact factor: 7.038

9.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

10.  Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.

Authors:  Frank J Attenello; Debraj Mukherjee; Ghazala Datoo; Matthew J McGirt; Eileen Bohan; Jon D Weingart; Alessandro Olivi; Alfredo Quinones-Hinojosa; Henry Brem
Journal:  Ann Surg Oncol       Date:  2008-07-18       Impact factor: 5.344

View more
  2 in total

1.  Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.

Authors:  Wei Hua; Chunjie Li; Zixiao Yang; Lihui Li; Yanan Jiang; Guangyang Yu; Wei Zhu; Zhengyan Liu; Shengzhong Duan; Yiwei Chu; Meng Yang; Yanmei Zhang; Ying Mao; Lijun Jia
Journal:  Neuro Oncol       Date:  2015-04-22       Impact factor: 12.300

Review 2.  An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013.

Authors:  Sophie Pietschmann; André O von Bueren; Guido Henke; Michael Josef Kerber; Rolf-Dieter Kortmann; Klaus Müller
Journal:  J Neurooncol       Date:  2014-08-27       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.